Key facts
- Notable investors include Catalio Capital Management, Mass General Brigham Ventures, Regeneron Ventures, The Column Group.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Monimoi Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Monimoi Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Monimoi Therapeutics
Developer of transformative therapies intended to harness the potential of covalent medicines and chemical proteomics. The company develops chemical proteins, innovative molecular technology with deep human translational insights for potential drug targets, enabling medical professionals to get the required support in developing drugs that target cancer-promoting proteins and innovate advanced treatments for cancer patients.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2025
- Employees
- 13
- Website
- monimoitx.com/
- Ownership
- Privately Held (backing)
Monimoi Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Monimoi Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Monimoi Therapeutics in its N-PORT filings yet. We sweep new filings monthly.